This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.
The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers
Age ≥ 18 years old and able to provide written informed consent;
Have not received any systemic or topical treatment for kidney/liver tumors.
Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.
The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc.
The subjects is known or suspected of other malignancies.
There has been another history of malignancy in the past 5 years.
Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.
All patients are in-hospital patients treated in Xinhua Hospital
Other
Cross-sectional
Blood test
Other interventionAbout 4 ml of blood draw
NMAP level study
To observe the difference in the expression level of nicotinamide metabolism related protein (NMAP) in the serum of newly diagnosed renal cancer and non-renal cancer patients. Draw the NMAP ROC curve and establish the appropriate Cut-off value to analyze its sensitivity and specificity.
NMAP plus other tumor biomarkers study
According to NMAP and combined with other tumor biomarkers data such as AFP, multiple regression analysis was used to map the ROC curve and establish the appropriate Cut-off value to determine whether it is capable of distinguishing kidney cancer and liver cancer.
Click on the lead sponsor to view all of their trials.
